Colorectal Cancer Biomarkers: Where Are We Now?

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Gonzalez Pons, Maria ^a,b   Cruz Correa, Marcia ^a,b,c  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; MICRORNA; NUCLEIC ACID; TUMOR MARKER; UNTRANSLATED RNA;

BLOOD ANALYSIS; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CPG ISLAND; EPIGENETICS; FECES ANALYSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; OCCULT BLOOD TEST; ONCOGENE K RAS; REVIEW; COLONOSCOPY; COLORECTAL NEOPLASMS; FECES; GENETICS; MOLECULAR PATHOLOGY; PATHOLOGY;

BIOMARKERS, TUMOR; COLONOSCOPY; COLORECTAL NEOPLASMS; FECES; HUMANS; MICRORNAS; PATHOLOGY, MOLECULAR;

EID: 84935883931     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/149014     Document Type: Review

References (145)

1. National Cancer Institute, SEER Cancer Statistics Factsheets: Colon and RectumCancer, NationalCancer Institute, Bethesda, Md, USA, http://seer.cancer. gov/statfacts/html/colorect.html.
2. American Cancer Society, Colorectal Cancer Facts and Figures 2014-2016, American Cancer Society, Atlanta, Ga, USA, 2014.
3. R. W. Burt, D. T. Bishop, H. T. Lynch, P. Rozen, and S. J. Winawer, "Risk and surveillance of individuals with heritable factors for colorectal cancer," Bulletin of the World Health Organization, vol. 68, no. 5, pp. 655-665, 1990.
4. S. J. Winawer, R. H. Fletcher, L. Miller et al., "Colorectal cancer screening: clinical guidelines and rationale," Gastroenterology, vol. 112, no. 2, pp. 594-642, 1997.
5. M. S. Kumar, "Biomarkers of disease in medicine," in Current Trends in Science, pp. 403-417, Indian Academy of Sciences, 2009.
6. Z. Huang, D. Huang, S. Ni, Z. Peng, W. Sheng, and X. Du, "Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer," International Journal of Cancer, vol. 127, no. 1, pp. 118-126, 2010.
7. N. I. Parikh and R. S. Vasan, "Assessing the clinical utility of biomarkers in medicine," Biomarkers in Medicine, vol. 1, no. 3, pp. 419-436, 2007.
8. T. Tanaka, M. Tanaka, and R. Ishigamori, "Biomarkers for colorectal cancer," International Journal of Molecular Sciences, vol. 11, no. 9, pp. 3209-3225, 2010.
9. M. F. Kane, M. Loda, G. M. Gaida et al., "Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines," Cancer Research, vol. 57, no. 5, pp. 808-811, 1997.
10. J. R. Jass, M. D. Walsh, M. Barker, L. A. Simms, J. Young, and B. A. Leggett, "Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability," European Journal of Cancer, vol. 38, no. 7, pp. 858-866, 2002.
11. A. D. Roth, S. Tejpar, M. Delorenzi et al., "Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial," Journal of Clinical Oncology, vol. 28, no. 3, pp. 466-474, 2010.
12. B. Iacopetta, F. Grieu, and B. Amanuel, "Microsatellite instability in colorectal cancer," Asia-Pacific Journal of Clinical Oncology, vol. 6, no. 4, pp. 260-269, 2010.
13. R. Gryfe, H. Kim, E. T. K. Hsieh et al., "Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer," The New England Journal of Medicine, vol. 342, no. 2, pp. 69-77, 2000.
14. S. Popat, R. Hubner, and R. S. Houlston, "Systematic review of microsatellite instability and colorectal cancer prognosis," Journal of Clinical Oncology, vol. 23, no. 3, pp. 609-618, 2005.
15. F. A. Sinicrope, R. L. Rego, K. C. Halling et al., "Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients," Gastroenterology, vol. 131, no. 3, pp. 729-737, 2006.
16. P. Benatti, R. Gafa, D. Barana et al., "Microsatellite instability and colorectal cancer prognosis," Clinical Cancer Research, vol. 11, no. 23, pp. 8332-8340, 2005.
17. S. R. Brown, P. J. Finan, N. R. Hall, and D. T. Bishop, "Incidence of DNA replication errors in patients with multiple primary cancers," Diseases of the Colon and Rectum, vol. 41, no. 6, pp. 765-769, 1998.
18. K. Shitoh, F. Konishi, Y. Miyakura, K. Togashi, T. Okamoto, and H. Nagai, "Microsatellite instability as a marker in predicting metachronous multiple colorectal carcinomas after surgery: a cohort-like study," Diseases of the Colon and Rectum, vol. 45, no. 3, pp. 329-333, 2002.
19. W.-S. Jo and J. M. Carethers, "Chemotherapeutic implications in microsatellite unstable colorectal cancer," Cancer Biomarkers, vol. 2, no. 1-2, pp. 51-60, 2006.
20. R. Jover, A. Castells, X. Llor, and M. Andreu, "Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer," Gut, vol. 55, no. 12, pp. 1819-1820, 2006.
21. C. Guastadisegni, M. Colafranceschi, L. Ottini, and E. Dogliotti, "Microsatellite instability as amarker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data," European Journal of Cancer, vol. 46, no. 15, pp. 2788-2798, 2010.
22. C. M. Ribic, D. J. Sargent, M. J. Moore et al., "Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer," The New England Journal of Medicine, vol. 349, no. 3, pp. 247-257, 2003.
23. M. M. Bertagnolli, D. Niedzwiecki, C. C. Compton et al., "Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803," Journal of Clinical Oncology, vol. 27, no. 11, pp. 1814-1821, 2009.
24. D. Fallik, F. Borrini, V. Boige et al., "Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer," Cancer Research, vol. 63, no. 18, pp. 5738-5744, 2003.
25. D. Cunningham, Y. Humblet, S. Siena et al., "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer,"The New England Journal of Medicine, vol. 351, no. 4, pp. 337-345, 2004.
26. J.-Y. Douillard, K. S. Oliner, S. Siena et al., "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer," The New England Journal of Medicine, vol. 369, no. 11, pp. 1023-1034, 2013.
27. W. de Roock, B. Claes, D. Bernasconi et al., "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis," The Lancet Oncology, vol. 11, no. 8, pp. 753-762, 2010.
28. G. Aprile, M. Macerelli, M. De, S. Pizzolitto, and G. Fasola, "The relevance of BRAF and extended RAS mutational analyses for metastatic colorectal cancer patients," OA Molecular Oncology, vol. 1, no. 1, article 7, 2013.
29. D. Kislitsin, A. Lerner, G. Rennert, and Z. Lev, "K-rasmutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes," Digestive Diseases and Sciences, vol. 47, no. 5, pp. 1073-1079, 2002.
30. J. Downward, "Targeting RAS signalling pathways in cancer therapy," Nature Reviews Cancer, vol. 3, no. 1, pp. 11-22, 2003.
31. W. D. Roock, V. D. Vriendt, N. Normanno, F. Ciardiello, and S. Tejpar, "KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer," The Lancet Oncology, vol. 12, no. 6, pp. 594-603, 2011.
32. W. S. Samowitz, K. Curtin, D. Schaffer, M. Robertson, M. Leppert, and M. L. Slattery, "Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study," Cancer Epidemiology, Biomarkers and Prevention, vol. 9, no. 11, pp. 1193-1197, 2000.
33. H. J. Andreyev, A. R. Norman, D. Cunningham et al., "Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study," British Journal of Cancer, vol. 85, no. 5, pp. 692-696, 2001.
34. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., "American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy," Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091-2096, 2009.
35. W. de Roock, H. Piessevaux, J. de Schutter et al., "KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab," Annals of Oncology, vol. 19, no. 3, pp. 508-515, 2008.
36. A. Lievre, J. B. Bachet, V. Boige et al., "KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab," Journal of Clinical Oncology, vol. 26, no. 3, pp. 374-379, 2008.
37. G. Wang, R. K. Kelley, and GAPPNet, "KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic," PLOS Currents, vol. 2, Article ID RRN1175, 2010.
38. H. Davies, G. R. Bignell, C. Cox et al., "Mutations of the BRAF gene in human cancer," Nature, vol. 417, no. 6892, pp. 949-954, 2002.
39. H. Rajagopalan, A. Bardelli, C. Lengauer, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu, "RAF/RAS oncogenes and mismatch-repair status," Nature, vol. 418, article 934, 2002.
40. A. de la Chapelle, G. Palomaki, and H. Hampel, "Identifying lynch syndrome," International Journal of Cancer, vol. 125, no. 6, pp. 1492-1493, 2009.
41. E. Domingo, P. Laiho, M. Ollikainen et al., "BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing," Journal of Medical Genetics, vol. 41, no. 9, pp. 664-668, 2004.
42. M. B. Loughrey, P. M. Waring, A. Tan et al., "Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer," Familial Cancer, vol. 6, no. 3, pp. 301-310, 2007.
43. T. Ikenoue, Y. Hikiba, F. Kanai et al., "Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors," Cancer Research, vol. 63, no. 23, pp. 8132-8137, 2003.
44. K. Fransen, M. Klintenas, A. Osterstrom, J. Dimberg, H.-J. Monstein, and P. Soderkvist, "Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas," Carcinogenesis, vol. 25, no. 4, pp. 527-533, 2004.
45. F. Di Nicolantonio, M. Martini, F. Molinari et al., "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer," Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705-5712, 2008.
46. R. Wong and D. Cunningham, "Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies," Journal of Clinical Oncology, vol. 26, no. 35, pp. 5668-5670, 2008.
47. E. van Cutsem, C.-H. Kohne, E. Hitre et al., "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer," The New England Journal of Medicine, vol. 360, no. 14, pp. 1408-1417, 2009.
48. A. Sartore-Bianchi, M. Martini, F. Molinari et al., "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies," Cancer Research, vol. 69, no. 5, pp. 1851-1857, 2009.
49. L. A. Aaltonen, P. Peltomaki, J.-P. Mecklin et al., "Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients," Cancer Research, vol. 54, no. 7, pp. 1645-1648, 1994.
50. S. M. Lipkin, V. Wang, D. L. Stoler et al., "Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: evidence for somatic mutation in colorectal cancers," Human Mutation, vol. 17, no. 5, pp. 389-396, 2001.
51. H. T. Lynch and A. de la Chapelle, "Hereditary colorectal cancer," The New England Journal of Medicine, vol. 348, no. 10, pp. 919-932, 2003.
52. J. M. D. Wheeler, A. Loukola, L. A. Aaltonen, N. J. McC Mortensen, and W. F. Bodmer, "The role of hypermethylation o the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers," Journal ofMedical Genetics, vol. 37, no. 8, pp. 588-592, 2000.
53. J.-P. Issa, "Colon cancer: its CIN or CIMP," Clinical Cancer Research, vol. 14, no. 19, pp. 5939-5940, 2008.
54. S. Popat and R. S. Houlston, "A systematic review and metaanalysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis," European Journal of Cancer, vol. 41, no. 14, pp. 2060-2070, 2005.
55. A. Walther, R. Houlston, and I. Tomlinson, "Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis," Gut, vol. 57, no. 7, pp. 941-950, 2008.
56. R. Jover, A. Paya, C. Alenda et al., "Defective mismatchrepair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis," The American Journal of Clinical Pathology, vol. 122, no. 3, pp. 389-394, 2004.
57. W. S. Samowitz, K. Curtin, K. N. Ma et al., "Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level," Cancer Epidemiology, Biomarkers and Prevention, vol. 10, no. 9, pp. 917-923, 2001.
58. S. Ogino, M. Cantor, T. Kawasaki et al., "CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies," Gut, vol. 55, no. 7, pp. 1000-1006, 2006.
59. S. Ogino, T. Kawasaki, G. J. Kirkner, P. Kraft, M. Loda, and C. S. Fuchs, "Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large populationbased sample," Journal ofMolecular Diagnostics, vol. 9, no. 3, pp. 305-314, 2007.
60. M. Toyota, N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin, and J.-P. J. Issa, "CpG islandmethylator phenotype in colorectal cancer," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 15, pp. 8681-8686, 1999.
61. M. Toyota, L. Shen, M. Ohe-Toyota, S. R. Hamilton, F. A. Sinicrope, and J.-P. J. Issa, "Aberrant methylation of the Cyclooxygenase CpG island in colorectal tumors," Cancer Research, vol. 60, no. 15, pp. 4044-4048, 2000.
62. N. M. Gatto, H. Frucht, V. Sundararajan, J. S. Jacobson, V. R. Grann, and A. I. Neugut, "Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study," Journal of the National Cancer Institute, vol. 95, no. 3, pp. 230-236, 2003.
63. C. D. Johnson, M. H. Chen, A. Y. Toledano et al., "Accuracy of CT colonography for detection of large adenomas and cancers," The New England Journal of Medicine, vol. 359, no. 12, pp. 1207-1217, 2008.
64. P. J. Pickhardt, J. R. Choi, I. Hwang et al., "Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults,"The New England Journal of Medicine, vol. 349, no. 23, pp. 2191-2200, 2003.
65. S. Summerton, E. Little, and M. S. Cappell, "CT colonography: current status and future promise," Gastroenterology Clinics of North America, vol. 37, no. 1, pp. 161-189, 2008.
66. J. A. Burch, K. Soares-Weiser, D. J. B. St John et al., "Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review," Journal of Medical Screening, vol. 14, no. 3, pp. 132-137, 2007.
67. D. L. Ouyang, J. J. Chen, R. H. Getzenberg, and R. E. Schoen, "Noninvasive testing for colorectal cancer: a review," The American Journal of Gastroenterology, vol. 100, no. 6, pp. 1393-1403, 2005.
68. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, "Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives," Genetics in Medicine, vol. 11, no. 1, pp. 35-41, 2009.
69. T. F. Imperiale, D. F. Ransohoff, S. H. Itzkowitz et al., "Multitarget stool DNA testing for colorectal-cancer screening," The New England Journal ofMedicine, vol. 370, no. 14, pp. 1287-1297, 2014.
70. S. W. An, N. K. Kim, and H. C. Chung, "Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening," YonseiMedical Journal, vol. 50, no. 3, pp. 331-334, 2009.
71. S. Tao, S. Hundt, U. Haug, and H. Brenner, "Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease," The American Journal of Gastroenterology, vol. 106, no. 2, pp. 242-253, 2011.
72. S. Ogino and A. Goel, "Molecular classification and correlates in colorectal cancer," Journal of Molecular Diagnostics, vol. 10, no. 1, pp. 13-27, 2008.
73. T. Kambara, L. A. Simms, V. L. J. Whitehall et al., "BRAF mutation is associated withDNAmethylation in serrated polyps and cancers of the colorectum," Gut, vol. 53, no. 8, pp. 1137-1144, 2004.
74. N. Hawkins, M. Norrie, K. Cheong et al., "CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability," Gastroenterology, vol. 122, no. 5, pp. 1376-1387, 2002.
75. M. van Rijnsoever, F. Grieu, H. Elsaleh, D. Joseph, and B. Iacopetta, "Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands," Gut, vol. 51, no. 6, pp. 797-802, 2002.
76. M. Toyota, M. Ohe-Toyota, N. Ahuja, and J.-P. J. Issa, "Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 710-715, 2000.
77. Y. Wang, T. Jatkoe, Y. Zhang et al., "Gene expression profiles and molecular markers to predict recurrence of Dukes B colon cancer," Journal of Clinical Oncology, vol. 22, no. 9, pp. 1564-1571, 2004.
78. A. Barrier, P.-Y. Boelle, F. Roser et al., "Stage II colon cancer prognosis prediction by tumor gene expression profiling," Journal of Clinical Oncology, vol. 24, no. 29, pp. 4685-4691, 2006.
79. S.-W. Jiang, J. Li, K. Podratz, and S. Dowdy, "Application ofDNA methylation biomarkers for endometrial cancer management," Expert Review of Molecular Diagnostics, vol. 8, no. 5, pp. 607-616, 2008.
80. R. Gray, J. Barnwell, C. McConkey, R. K. Hills, N. S. Williams, and D. J. Kerr, "Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study," The Lancet, vol. 370, no. 9604, pp. 2020-2029, 2007.
81. Y. Ma, P. Zhang, J. Yang, Z. Liu, Z. Yang, and H. Qin, "Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation," International Journal of Cancer, vol. 130, no. 9, pp. 2077-2087, 2011.
82. S. Khambata-Ford, C. R. Garrett, N. J. Meropol et al., "Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treatedwith cetuximab," Journal of ClinicalOncology, vol. 25, no. 22, pp. 3230-3237, 2007.
83. B. Jacobs, W. de Roock, H. Piessevaux et al., "Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab," Journal of ClinicalOncology, vol. 27, no. 30, pp. 5068-5074, 2009.
84. J. B. Baker, D. Dutta, D. Watson et al., "Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer," British Journal of Cancer, vol. 104, no. 3, pp. 488-495, 2011.
85. K. E. Bachman, P. Argani, Y. Samuels et al., "The PIK3CA gene is mutated with high frequency in human breast cancers," Cancer Biology andTherapy, vol. 3, no. 8, pp. 772-775, 2004.
86. Y. Samuels, L. A. Diaz Jr., O. Schmidt-Kittler et al., "Mutant PIK3CA promotes cell growth and invasion of human cancer cells," Cancer Cell, vol. 7, no. 6, pp. 561-573, 2005.
87. M. Frattini, P. Saletti, E. Romagnani et al., "PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients," British Journal ofCancer, vol. 97, no. 8, pp. 1139-1145, 2007.
88. N. K. OsbornandD. A. Ahlquist, "Stool screening for colorectal cancer: molecular approaches," Gastroenterology, vol. 128, no. 1, pp. 192-206, 2005.
89. J. S. Mandel, J. H. Bond, T. R. Church et al., "Reducingmortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study," The New England Journal of Medicine, vol. 328, no. 19, pp. 1365-1371, 1993.
90. O. Kronborg, C. Fenger, J. Olsen, O. D. Jorgensen, and O. Sondergaard, "Randomised study of screening for colorectal cancer with faecal-occult-blood test," The Lancet, vol. 348, no. 9040, pp. 1467-1471, 1996.
91. J. D. Hardcastle, J. O. Chamberlain, M. H. E. Robinson et al., "Randomised controlled trial of faecal-occult-blood screening for colorectal cancer," The Lancet, vol. 348, no. 9040, pp. 1472-1477, 1996.
92. P. Hewitson, P. Glasziou, E. Watson, B. Towler, and L. Irwig, "Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update," American Journal of Gastroenterology, vol. 103, no. 6, pp. 1541-1549, 2008.
93. F. A. Oort, J. S. T. S. Droste, R. W. M. van der Hulst et al., "Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test," Alimentary Pharmacology andTherapeutics, vol. 31, no. 3, pp. 432-439, 2010.
94. L. G. M. van Rossum, A. F. van Rijn, I. P. vanMunster et al., "Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests," Netherlands Journal of Medicine, vol. 67, no. 5, pp. 182-186, 2009.
95. B. Levin, D. Brooks, R. A. Smith, and A. Stone, "Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers," CA: A Cancer Journal for Clinicians, vol. 53, no. 1, pp. 44-55, 2003.
96. W.-D. Chen, Z. J. Han, J. Skoletsky et al., "Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene," Journal of the National Cancer Institute, vol. 97, no. 15, pp. 1124-1132, 2005.
97. H. Zou, J. J. Harrington, A. M. Shire et al., "Highly methylated genes in colorectal neoplasia: implications for screening," Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 12, pp. 2686-2696, 2007.
98. D. Sidransky, T. Tokino, S. R. Hamilton et al., "Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors," Science, vol. 256, no. 5053, pp. 102-105, 1992.
99. T. Sjoblom, S. Jones, L. D. Wood et al., "The consensus coding sequences of human breast and colorectal cancers," Science, vol. 314, no. 5797, pp. 268-274, 2006
100. M. J. Makinen, "Colorectal serrated adenocarcinoma," Histopathology, vol. 50, no. 1, pp. 131-150, 2007.
101. T. Takai, S. Kanaoka, K.-I. Yoshida et al., "Fecal cyclooxygenase plus matrixmetalloproteinase7mRNA assays as a marker for colorectal cancer screening," Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 6, pp. 1888-1893, 2009.
102. A. Link, F. Balaguer, Y. Shen et al., "Fecal microRNAs as novel biomarkers for colon cancer screening," Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 7, pp. 1766-1774, 2010.
103. A. C. von Roon, L. Karamountzos, S. Purkayastha et al., "Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectalmalignancy,"TheAmerican Journal of Gastroenterology, vol. 102, no. 4, pp. 803-813, 2007.
104. P. X. Xing, G. P. Young, D. Ho, M. A. Sinatra, P. B. Hoj, and I. F. McKenzie, "A new approach to fecal occult blood testing based on the detection of haptoglobin," Cancer, vol. 78, no. 1, pp. 48-56, 1996.
105. I. K. Quaye, "Haptoglobin, inflammation and disease," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 102, no. 8, pp. 735-742, 2008.
106. G. Y. Locker, S. Hamilton, J. Harris et al., "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer," Journal of Clinical Oncology, vol. 24, no. 33, pp. 5313-5327, 2006.
107. S. Hundt, U. Haug, and H. Brenner, "Blood markers for early detection of colorectal cancer: a systematic review," Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 10, pp. 1935-1953, 2007.
108. K. Jung, M. Fleischhacker, and A. Rabien, "Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature," Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1611-1624, 2010.
109. M. Frattini, G. Gallino, S. Signoroni et al., "Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer," Cancer Letters, vol. 263, no. 2, pp. 170-181, 2008.
110. N. Umetani, J. Kim, S. Hiramatsu et al., "Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR forALUrepeats," Clinical Chemistry, vol. 52, no. 6, pp. 1062-1069, 2006.
111. P. Anker, F. Lefort, V. Vasioukhin et al., "K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer,"Gastroenterology, vol. 112, no. 4, pp. 1114-1120, 1997.
112. J. B. de Kok, W. W. van Solinge, T. J. M. Ruers et al., "Detection of tumour DNA in serum of colorectal cancer patients," Scandinavian Journal of Clinical and Laboratory Investigation, vol. 57, no. 7, pp. 601-604, 1997.
113. M. S. Kopreski, F. A. Benko, C. Kwee et al., "Detection ofmutant K-ras DNA in plasma or serum of patients with colorectal cancer," British Journal of Cancer, vol. 76, no. 10, pp. 1293-1299, 1997.
114. M. Li, W.-D. Chen, N. Papadopoulos et al., "Sensitive digital quantification of DNA methylation in clinical samples," Nature Biotechnology, vol. 27, no. 9, pp. 858-863, 2009.
115. R. Grutzmann, B. Molnar, C. Pilarsky et al., "Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay," PLoS ONE, vol. 3, no. 11, Article ID e3759, 2008.
116. C. Lofton-Day, F. Model, T. DeVos et al., "DNA methylation biomarkers for blood-based colorectal cancer screening," Clinical Chemistry, vol. 54, no. 2, pp. 414-423, 2008.
117. R. E. Board, L. Knight, A. Greystoke et al., "DNA methylation in circulating tumour DNA as a biomarker for cancer," Biomarker Insights, vol. 2, pp. 307-319, 2008.
118. T. deVos, R. Tetzner, F. Model et al., "Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer," Clinical Chemistry, vol. 55, no. 7, pp. 1337-1346, 2009.
119. C. P. E. Lange, M. Campan, T. Hinoue et al., "Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer," PLoS ONE, vol. 7, no. 11, Article ID e50266, 2012.
120. R. Douard, S. Moutereau, V. Serru et al., "Immunobead multiplex RT-PCR detection of carcinoembryonic genes expressing cells in the blood of colorectal cancer patients," Clinical Chemistry and Laboratory Medicine, vol. 43, no. 2, pp. 127-132, 2005.
121. C. Shen, L. Hu, L. Xia, and Y. Li, "Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients," Japanese Journal of Clinical Oncology, vol. 38, no. 11, pp. 770-776, 2008.
122. J. Y. Wang, C. S. Yeh, Y. F. Chen et al., "Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patientswith colorectal cancer," International Journal of Molecular Medicine, vol. 17, no. 5, pp. 737-747, 2006.
123. D. Xu, X.-F. Li, S. Zheng, and W.-Z. Jiang, "Quantitative realtime RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients," Journal of Zhejiang University SCIENCE B, vol. 7, no. 6, pp. 445-451, 2006.
124. C.-S. Yeh, J.-Y. Wang, C.-H. Wu et al., "Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by usingmembrane array with amultiple mRNAmarker panel," International Journal ofOncology, vol. 28, no. 2, pp. 411-420, 2006.
125. S. M. Lledo, E. Garcia-Granero, F. Dasi et al., "Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer," Colorectal Disease, vol. 6, no. 4, pp. 236-242, 2004.
126. R. Douard, V. LeMaire, P. Wind et al., "Carcinoembryonic gene member 2 mRNA expression as a marker to detect circulating enterocytes in the blood of colorectal cancer patients," Surgery, vol. 129, no. 5, pp. 587-594, 2001.
127. I. Miyashiro, C. Kuo, K. Huynh et al., "Molecular strategy for detectingmetastatic cancerswith use ofmultiple tumor-specific MAGE-A genes," Clinical Chemistry, vol. 47, no. 3, pp. 505-512, 2001.
128. V. Garcia, J. M. Garcia, C. Pena et al., "Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential," Clinical Cancer Research, vol. 12, no. 7, part 1, pp. 2095-2100, 2006.
129. S. A. Bustin, V. G. Gyselman, N. S. Williams, and S. Dorudi, "Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients," British Journal of Cancer, vol. 79, no. 11-12, pp. 1813-1820, 1999.
130. T. H. K. Schiedeck, C. Wellm, U. J. Roblick, R. Broll, and H.-P. Bruch, "Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzymelinked immunosorbent assay," Diseases of the Colon and Rectum, vol. 46, no. 6, pp. 818-825, 2003.
131. X. Chen, Y. Ba, L. Ma et al., "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases," Cell Research, vol. 18, no. 10, pp. 997-1006, 2008.
132. Z. Kanaan, H. Roberts, M. R. Eichenberger et al., "A plasma MicroRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer," Annals of Surgery, vol. 258, no. 3, pp. 400-406, 2013.
133. F. L. Yong, C. W. Law, and C. W. Wang, "Potentiality of a triple microRNA classifier: MiR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer," BMC Cancer, vol. 13, article 280, 2013.
134. E. K. O. Ng, W. W. S. Chong, H. Jinet al., "Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening," Gut, vol. 58, no. 10, pp. 1375-1381, 2009.
135. P. Menendez, D. Padilla, P. Villarejo et al., "Prognostic implications of serum microRNA-21 in colorectal cancer," Journal of Surgical Oncology, vol. 108, no. 6, pp. 369-373, 2013.
136. M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen et al., "Total levels of tissue inhibitor ofmetalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer," Clinical Cancer Research, vol. 8, no. 4, pp. 156-164, 2002.
137. I. Babel, R. Barderas, R. Diaz-Uriarte, J. L. Martinez-Torrecuadrada, M. Sanchez-Carbayo, and J. I. Casal, "Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays," Molecular and Cellular Proteomics, vol. 8, no. 10, pp. 2382-2395, 2009.
138. E. S. Leman, R. E. Schoen, A. Magheli, L. J. Sokoll, D. W. Chan, and R. H. Getzenberg, "Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer," Clinical Cancer Research, vol. 14, no. 5, pp. 1349-1354, 2008.
139. E. S. Leman, R. E. Schoen, J. L. Weissfeld et al., "Initial analyses of Colon Cancer-Specific Antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serummarkers," Cancer Research, vol. 67, no. 12, pp. 5600-5605, 2007.
140. M. S. Kim, J. Louwagie, B. Carvalho et al., "Promoter DNA methylation of oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer," PLoS ONE, vol. 4, no. 8, Article ID e6555, 2009.
141. N. G. Hurst, D. D. Stocken, S. Wilson, C. Keh, M. J. O. Wakelam, and T. Ismail, "Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients," British Journal of Cancer, vol. 97, no. 7, pp. 971-977, 2007.
142. J. Sastre, M. L. Maestro, J. Puente et al., "Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables," Annals of Oncology, vol. 19, no. 5, pp. 935-938, 2008.
143. S. J. Cohen, C. J. Punt, N. Iannotti et al., "Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer," Journal of Clinical Oncology, vol. 26, no. 19, pp. 3213-3221, 2008.
144. S. J. Cohen, C. J. A. Punt, N. Iannotti et al., "Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer," Annals of Oncology, vol. 20, no. 7, pp. 1223-1229, 2009.
145. Y.-H. Uen, C.-Y. Lu, H.-L. Tsai et al., "Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection," Annals of Surgical Oncology, vol. 15, no. 8, pp. 2120-2128, 2008.